Puma Biotechnology Inc. (PBYI)

16.59
NASDAQ : Health Technology
Prev Close 16.88
Day Low/High 16.58 / 17.13
52 Wk Low/High 15.96 / 65.45
Avg Volume 1.24M
Exchange NASDAQ
Shares Outstanding 38.61M
Market Cap 651.77M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Hold on Tight: Cramer's 'Mad Money' Recap (Monday 5/13/19)

Hold on Tight: Cramer's 'Mad Money' Recap (Monday 5/13/19)

Fasten your seatbelt, says Jim Cramer. Trade tensions are making for a wild ride on Wall Street, but stocks are almost in oversold territory.

Disney, 21st Century Fox, Village Farms: 'Mad Money' Lightning Round

Disney, 21st Century Fox, Village Farms: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Disney, 21st Century Fox, Village Farms, SailPoint Technologies, Magellan Midstream Partners, Becton Dickinson, Puma Biotechnology, Parsons and more.

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Shares of Puma Biotechnology plunge after the company reveals that more patients than expected have discontinued treatment with its breast cancer drug, Nerlynx, prompting several analyst downgrades.

Puma Biotechnology Reports First Quarter 2019 Financial Results

Puma Biotechnology Reports First Quarter 2019 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2019.

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference 2019

Puma Biotechnology To Present At Bank Of America Merrill Lynch Health Care Conference 2019

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 3, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 49,125...

Puma Biotechnology To Host Conference Call To Discuss First Quarter Financial Results

Puma Biotechnology To Host Conference Call To Discuss First Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 3, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 45,625...

Puma Biotechnology Expands Cohorts In Phase II SUMMIT Trial Of Neratinib In Cancer Patients With Tumors With Activating EGFR Or HER2 Mutations

Puma Biotechnology Expands Cohorts In Phase II SUMMIT Trial Of Neratinib In Cancer Patients With Tumors With Activating EGFR Or HER2 Mutations

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or...

Puma Biotechnology And Pierre Fabre Enter Into Exclusive License Agreement To Develop And Commercialize NERLYNX® (neratinib) In Europe

Puma Biotechnology And Pierre Fabre Enter Into Exclusive License Agreement To Develop And Commercialize NERLYNX® (neratinib) In Europe

Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX® (neratinib) within Europe and part of Africa.

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For AACR Annual Meeting 2019

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For AACR Annual Meeting 2019

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2019.

Puma Biotechnology Presents Interim Results From The Phase II SUMMIT Trial Of Neratinib For HER2 (ERBB2) Mutant, Metastatic Cervical Cancer At The Society Of Gynecologic Oncology (SGO) 2019 Annual Meeting

Puma Biotechnology Presents Interim Results From The Phase II SUMMIT Trial Of Neratinib For HER2 (ERBB2) Mutant, Metastatic Cervical Cancer At The Society Of Gynecologic Oncology (SGO) 2019 Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that updated results from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were...

Puma Biotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval To Commercialize NERLYNX® (neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval To Commercialize NERLYNX® (neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) to commercialize NERLYNX® (neratinib) in...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 12, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,688...

Puma Biotechnology To Present At Cowen's Annual Health Care Conference

Puma Biotechnology To Present At Cowen's Annual Health Care Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Reports Fourth Quarter And Full Year 2018 Financial Results

Puma Biotechnology Reports Fourth Quarter And Full Year 2018 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018.

April 12th Options Now Available For Puma Biotechnology (PBYI)

April 12th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available today, for the April 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new April 12th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 14, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375...

Puma Biotechnology To Host Conference Call To Discuss Fourth Quarter And Full Year Financial Results

Puma Biotechnology To Host Conference Call To Discuss Fourth Quarter And Full Year Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

PBYI March 29th Options Begin Trading

PBYI March 29th Options Begin Trading

Investors in Puma Biotechnology Inc saw new options become available today, for the March 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new March 29th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Announces Litigation Victory With Jury's Decision

Puma Biotechnology Announces Litigation Victory With Jury's Decision

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that the class action lawsuit, Hsu vs.

Interesting PBYI Put And Call Options For March 22nd

Interesting PBYI Put And Call Options For March 22nd

Investors in Puma Biotechnology Inc saw new options begin trading today, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.

Puma Biotechnology And Knight Therapeutics Enter Into Exclusive License Agreement To Commercialize NERLYNX® (neratinib) In Canada

Puma Biotechnology And Knight Therapeutics Enter Into Exclusive License Agreement To Commercialize NERLYNX® (neratinib) In Canada

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc.

First Week Of February 8th Options Trading For Puma Biotechnology (PBYI)

First Week Of February 8th Options Trading For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available this week, for the February 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new February 8th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology To Present At J. P. Morgan Healthcare Conference

Puma Biotechnology To Present At J. P. Morgan Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

February 22nd Options Now Available For Puma Biotechnology (PBYI)

February 22nd Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available today, for the February 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new February 22nd contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 30, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 10,750...

Puma Biotechnology Announces Top Line Results Of The Phase III NALA Trial Of Neratinib In Patients With HER2-Positive Metastatic Breast Cancer

Puma Biotechnology Announces Top Line Results Of The Phase III NALA Trial Of Neratinib In Patients With HER2-Positive Metastatic Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced top line results from the Phase III NALA trial of the Company's lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed...

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Maximo F.

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Maximo F.

TheStreet Quant Rating: D- (Sell)